Disclosure of Results. In addition to Aurigene’s obligations to deliver Aurigene Immuno-oncology PTP Data Packages, Development Candidate Data Packages and Follow-On Molecule Profile Data Packages in accordance with Sections 3.1(b)(ii), 3.6 and 3.8, respectively, Aurigene shall keep Curis regularly informed, primarily via the SOC, of the progress and results of all R&D Plan activities and the status of patent filings with respect to Program Inventions.
Disclosure of Results. (a) IND-Enabling Studies and Aurigene CMC Activities. Aurigene shall deliver to Curis the draft and final study reports for each IND-enabling study and disclose to Curis all results of Aurigene CMC Activities performed by or on behalf of Aurigene under a Development Plan, in each case, promptly following the availability thereof.
Disclosure of Results. Akcea will promptly disclose to Novartis through the CSC the results of all work performed by Akcea under the Pre-Option Development Plan (including activities under SCHEDULE 1.3.2) in a reasonable manner as such results are obtained. Akcea will provide reports and analyses at each CSC meeting detailing the current status of each Product under the Pre-Option Development Plan together with a summary of the data generated by Akcea under such plan. Furthermore, during the Option Period, Akcea shall promptly notify Novartis of, and promptly provide to Novartis, all data and/or information in the possession of or readily available to Akcea relating to a Product that Akcea generates before the end of the Option Period that would be relevant for Novartis’ decision concerning the exercise of the Option, as well as any such data and information specifically requested by Novartis during the Option Period. Novartis shall provide [***] on the [***] at each [***] together with a [***] or other [***] generated by [***] from conducting such [***]. If reasonably requested [***], Novartis shall [***] that Novartis has not previously [***] under this Agreement. The results, reports, analyses and other information regarding the Products disclosed by one Party to the other Party pursuant hereto may be used only in accordance with the rights granted and other terms and conditions under this Agreement. Any reports required under this Section 1.2.7 may take the form of and be recorded in minutes of the CSC that will contain copies of any slides relating to the results and presented to the CSC.
Disclosure of Results. The results of any drug test administered by the Agency for any reason may not be disclosed without the prior written consent of the employee. This requirement will not apply to disclosure to the Agency Medical Review Officer, the Employee Assistance Program, to the Agency officials involved in taking disciplinary actions, the employee, or to other authorized government officials who have the need to know. It is the Agency's responsibility to ensure that it discloses information only to authorized officials.
Disclosure of Results. The results of such inspections and studies (as well as any information and documents that Seller delivered or caused to be delivered to Purchaser concerning the Timberlands) shall be treated as strictly confidential by Purchaser and the same shall not be disclosed to any third party or Governmental Authority (provided that such results, information and documents may be disclosed to consultants, attorneys, investors and lenders of Purchaser for use solely in connection with the transactions contemplated by this Agreement, who shall be required by Purchaser to similarly treat such results, information and documents as strictly confidential) except to the extent required by any Law or court order or in connection with any legal proceeding filed to enforce a Party’s rights under this Agreement. In the event that disclosure of the results of any such inspection or study or any such information or document that Seller delivered or caused to be delivered to Purchaser concerning the Timberlands is required by applicable Law or court order, Purchaser shall notify Seller promptly in writing so that Seller may seek a protective order (at its own cost and expense) or other appropriate remedy or, in its sole discretion, waive compliance with the terms of this Section 7.1(b). Purchaser shall reasonably cooperate with Seller, at Seller’s sole cost and expense, to obtain a protective order or other appropriate remedy. In the event that no such protective order or other appropriate remedy is obtained, or Seller waives compliance with the terms of this Section 7.1(b), Purchaser shall give Seller written notice of the information to be disclosed as far in advance of its disclosure as practicable. In the event this Agreement is terminated for any reason, Purchaser, at no additional cost to Purchaser, will promptly furnish to Seller copies of all such inspections or studies performed by or on behalf of Purchaser with respect to the Property; provided, however, that Purchaser shall not be required to provide Seller with copies of appraisals, marketing, or financial analysis, generated or made by or on behalf of Purchaser and those documents or reports which are protected by the attorney-client and/or attorney work product privileges. Purchaser does not make any warranty regarding the content or accuracy of any such information. If Seller wishes to use or rely on such inspections or studies, Seller shall have the responsibility, at Seller’s cost, to obtain any necessary consent...
Disclosure of Results. During the Research Period, Arcturus shall keep Providence regularly informed, primarily via the JSC and the Alliance Managers, of the progress and results of Research Program activities. Without limiting the generality of the foregoing, Arcturus shall provide to Providence written reports of the Research Program activities performed by or on behalf of Arcturus, and all data and results generated or achieved in such activities, reasonably in advance of each regularly-scheduled meeting of the JSC. Arcturus will only disclose composition and sequence of the Licensed LUNAR Formulation.
Disclosure of Results. Each Party shall keep the other Party regularly informed, primarily via the JSC and the Alliance Managers, of the progress and results of Development activities, including a detailed written quarterly report of its progress.
Disclosure of Results. At a PC Entity’s request, the Company shall disclose the results of such inspections and studies, and shall deliver copies of all reports and test results, to the PC Entities. The results of such inspections and studies (as well as any information and documents that Plum Creek or PC Member (or any of their Affiliates) delivered or caused to be delivered to the Company concerning the Timberlands) shall be treated as strictly confidential by the Parties and the same shall not be disclosed by the Company or any of its employees, representatives or agents to any third party or Governmental Authority (provided that such results, information and documents may be disclosed to consultants, managers (including Silver Creek), attorneys, investors and lenders of the Company for use solely in connection with the transactions contemplated by this Agreement, who shall be required by the Company to similarly treat such results, information and documents as strictly confidential) except to the extent required by any Law or court order or in connection with any legal proceeding filed to enforce a Party’s rights under this Agreement. In the event that disclosure of the results of any such inspection or study or any such information or document that a PC Entity delivered or caused to be delivered to the Company concerning the Timberlands is required by applicable Law or court order, the Company shall notify the PC Entities promptly in writing so that the PC Entities may seek a protective order (at their own cost and expense) or other appropriate remedy or, in its sole discretion, waive compliance with the terms of this Section 9.1(b). The Company shall cooperate (at no cost or expense to the Company) with the PC Entities to obtain a protective order or other appropriate remedy. In the event that no such protective order or other appropriate remedy is obtained, or the PC Entities waive compliance with the terms of this Section 9.1(b), the Company shall give the PC Entities written notice of the information to be disclosed as far in advance of its disclosure as practicable.
Disclosure of Results. Subject to Section 7.6 (Publications), each Party may publish or promote any Results of that Party (but for clarity, not of Results obtained by the other Party). Each Party may publish or promote any Results of the other Party if permitted under Section 7.4, or with the prior consent of the other Party (not to be unreasonably withheld, conditioned or delayed), in each case after providing the other Party with as much notice as is reasonably practicable. The Party intending to disclose any Results shared by the other Party shall disclose such intended publication to the other Party shall postpone any portion of the publication for an additional period of up to [***], to permit the filing of a patent application and shall reasonably take into account any comments and recommendations of such other Party prior to publication.
Disclosure of Results. At least [***] Business Days prior to each regularly scheduled meeting of the JRC, each Party will provide to the JRC a written report (which may take the form of PowerPoint slides) for each Drug Discovery Program (i) describing the Drug Discovery Program activities performed by such Party since the date of the preceding written report delivered by such Party for such Drug Discovery Program and the status of each such activity as of the date of such report and (ii) summarizing the data and results of the Drug Discovery Program activities performed by such Party under the applicable Plan.
